SCHEMBL6926925

SCHEMBL6926925

O=S(=O)(Nc1ccccc1Br)c1ccc2[nH]c(-c3ccccc3)nc2c1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 12/20 0.66
TP53 P04637 8/20 0.60
MEN1 O00255 2/20 0.59
LMNA P02545 2/20 0.59
KMT2A Q03164 2/20 0.59
NPBWR1 P48145 1/20 0.51
MMP2 P08253 1/20 0.51
MMP9 P14780 1/20 0.51
MMP8 P22894 1/20 0.51
MMP13 P45452 1/20 0.51
SMN1; SMN2 Q16637 3/20 0.51
SCD O00767 1/20 0.49
HDAC6 Q9UBN7 1/20 0.48
KDM4E B2RXH2 1/20 0.46
ALDH1A1 P00352 1/20 0.46
GAA P10253 1/20 0.46
HPGD P15428 1/20 0.46
MAPK1 P28482 1/20 0.46
CHEK2 O96017 1/20 0.45
POLB P06746 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6926045 0.87 MAPT (0.67) MAPTTP53MEN1LMNAKMT2A
SCHEMBL6926782 0.86 MAPT (0.66) MAPTTP53MEN1LMNAKMT2A
SCHEMBL6926524 0.81 MAPT (0.68) MAPTTP53MEN1LMNAKMT2A
SCHEMBL6926841 0.79 MAPT (0.57) MAPTTP53MEN1LMNAKMT2A
SCHEMBL12568424 0.79 NPBWR1 (0.79) NPBWR1SCDHDAC6CYP1A2CYP2C9
SCHEMBL15640415 0.79 CHEK2 (0.63) MAPTTP53NPBWR1MMP2MMP9
SCHEMBL6926526 0.77 MMP2 (0.57) MAPTTP53MEN1LMNAKMT2A
SCHEMBL15793143 0.77 MAPT (0.63) MAPTTP53MEN1KMT2AMMP2
SCHEMBL6926099 0.77 MAPT (0.55) MAPTTP53MEN1LMNAKMT2A
SCHEMBL11370727 0.76 MAPT (0.62) MAPTTP53MEN1LMNAKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120184556-A1 SUBSTITUTED ENZOIMIDAZOLESULFONAMIDES AND SUBSTITUTED INDOLESULFONAMIDES AS MGLUR4 POTENTIATORS NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR 2012-07-19 US disclosed
US-20120184556-A1 SUBSTITUTED ENZOIMIDAZOLESULFONAMIDES AND SUBSTITUTED INDOLESULFONAMIDES AS MGLUR4 POTENTIATORS NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR 2012-07-19 US disclosed
US-20120184556-A1 SUBSTITUTED ENZOIMIDAZOLESULFONAMIDES AND SUBSTITUTED INDOLESULFONAMIDES AS MGLUR4 POTENTIATORS NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR 2012-07-19 US disclosed
WO-2011011722-A1 SUBSTITUTED BENZOIMIDAZOLESULFONAMIDES AND SUBSTITUTED INDOLESULFONAMIDES AS MGLUR4 POTENTIATORS VANDERBILT UNIVERSITY (US) 2011-01-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120184556-A1 SUBSTITUTED ENZOIMIDAZOLESULFONAMIDES AND SUBSTITUTED INDOLESULFONAMIDES AS MGLUR4 POTENTIATORS GRM4, GRIK4, GRIA4 MAPT 3868/4885TP53 4875/4885MEN1 4390/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.